- Entry
- $2.38
- Now
- $0.5073 -78.7%
- Target
- —
- Score
- —
I've been watching Context Therapeutics (CNTX) for a while and wanted to lay out why I think the setup here is interesting. Currently sitting at ~$2.39. **What they do** Context is a clinical-stage biotech developing bispecific antibodies for solid tumors. Their lead drug is CTIM-76, which targets Claudin 6 (CLDN6), a protein that shows up across ovarian, endometrial, lung, gastric, and testicular cancers. The initial focus is platinum-resistant ovarian cancer, which is a brutal diagnosis with very limited treatment options. …
— ORIGINAL POST ·
CNTX - 3 data catalysts in 5 months, FDA Fast Track, and $54M cash. Here's the DD.
· r/pennystocks
· May 10, 2026